01—Abstract
Summary
Summary of the 8-K filed May 20, 2024. Cited figures are marked; the original filing is the authoritative source.
Alnylam Pharmaceuticals, Inc. (ALNY) held its 2024 Annual Meeting of Stockholders on May 16, 2024, with a filing on May 20, 2024, detailing the outcomes of key votes.
The meeting saw the overwhelming re-election of four Class II directors: Dennis A. Ausiello, M.D., Olivier Brandicourt, M.D., Peter N. Kellogg, and David E.I.
Pyott, each receiving substantial support from shareholders to serve until the 2027 annual meeting. This demonstrates continued confidence in the board's leadership and strategic direction. Furthermore, Alnylam's stockholders overwhelmingly approved the compensation of the company's named executive officers in a non-binding advisory vote, indicating shareholder alignment with the company's executive compensation policies.
The appointment of PricewaterhouseCoopers LLP as the independent auditor for the fiscal year ending December 31, 2024, was also overwhelmingly ratified, reinforcing the company's commitment to robust financial oversight and transparent reporting. The strong voting results across these critical matters suggest a stable and supportive shareholder base.
02—Key points
Key Highlights
- Four Class II directors (Dennis A. Ausiello, M.D., Olivier Brandicourt, M.D., Peter N. Kellogg, David E.I. Pyott) were re-elected with significant majority support, extending their terms until the 2027 annual meeting.
- The compensation of Alnylam's named executive officers was approved by stockholders in a non-binding advisory vote, showing general shareholder agreement with executive pay practices.
- The appointment of PricewaterhouseCoopers LLP as the independent auditor for the fiscal year ending December 31, 2024, was ratified with strong shareholder approval.
- A high number of shares were issued and outstanding as of the record date (March 22, 2024), totaling 126,452,099 shares of common stock.
- Director re-elections garnered over 100 million 'Votes For' each, indicating broad shareholder confidence in the nominated individuals.
- The 'Say-on-Pay' vote received approximately 106.8 million 'Votes For', highlighting strong support for executive compensation packages.
- The ratification of the independent auditor received over 114 million 'Votes For', reflecting shareholder confidence in the company's audit and financial reporting processes.
03—Questions
Frequently Asked Questions
What were the main outcomes of Alnylam's 2024 Annual Meeting of Stockholders?
The primary outcomes were the re-election of four Class II directors, the approval of named executive officer compensation through a non-binding advisory vote, and the ratification of PricewaterhouseCoopers LLP as the company's independent auditor for fiscal year 2024. All these proposals received strong majority support from stockholders.
How did the shareholders vote on the re-election of directors?
Shareholders overwhelmingly re-elected Dennis A. Ausiello, M.D., Olivier Brandicourt, M.D., Peter N. Kellogg, and David E.I. Pyott. Each director received well over 100 million 'Votes For', with 'Votes Against' and 'Abstentions' representing a small fraction of the total votes cast.
What is the significance of the non-binding advisory vote on executive compensation?
The non-binding advisory vote, often referred to as 'Say-on-Pay', allows shareholders to express their opinion on the company's executive compensation philosophy and practices. The strong approval of Alnylam's executive compensation indicates that a significant majority of shareholders are satisfied with how the company compensates its top executives.
Was there any opposition or significant concern raised by the voting results?
While all proposals passed with strong majorities, there were some 'Votes Against' and 'Abstentions' on the director re-elections and the executive compensation vote. Specifically, David E.I. Pyott received the highest number of 'Votes Against' among the re-elected directors. Investors may wish to monitor any ongoing concerns related to these specific votes in future communications.
04—Continue